| Literature DB >> 31392204 |
Abstract
Pompe disease is a multisystemic metabolic disorder caused by a deficiency of lysosomal acid alpha-glucosidase (GAA) leading to progressive accumulation of lysosomal glycogen, lysosomal swelling and rupture in all tissues of the human body. Furthermore, autophagic buildup, organelle abnormalities, and energy deficit are regularly observed. Enzyme replacement therapy has been available for patients living with Pompe disease for more than 15 years. Although our disease knowledge has grown enormously, we still have multiple challenges to overcome. Here, I will discuss unmet clinical needs, neglected or overlooked aspects of the pathophysiology, and issues related to future therapies.Entities:
Keywords: Pompe disease; axial myopathy; energy metabolism; enzyme replacement therapy (ERT); fatigue; gene therapy; unmet needs
Year: 2019 PMID: 31392204 PMCID: PMC6642932 DOI: 10.21037/atm.2019.05.29
Source DB: PubMed Journal: Ann Transl Med ISSN: 2305-5839